Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
This is precisely where StockStory comes in - we do the heavy lifting to identify companies with solid fundamentals so you can invest with confidence. Keeping that in mind, here is one mid-cap stock with a long growth runway and two best left ignored.
Two Mid-Cap Stocks to Sell:
F5 (FFIV)
Market Cap: $23.05 billion
Originally named after the F5 tornado, the most powerful on the meteorological scale, F5 (NASDAQ: FFIV) provides security and delivery solutions that protect applications across cloud, data center, and edge environments for large organizations.
Why Do We Think Twice About FFIV?
- Average billings growth of 11.3% over the last year was subpar, suggesting it struggled to push its software and might have to lower prices to stimulate demand
- Estimated sales growth of 7.6% for the next 12 months implies demand will slow from its two-year trend
- Static operating margin over the last year shows it couldn’t become more efficient
F5’s stock price of $406.56 implies a valuation ratio of 6.4x forward price-to-sales. Check out our free in-depth research report to learn more about why FFIV doesn’t pass our bar.
West Pharmaceutical Services (WST)
Market Cap: $24.01 billion
Founded in 1923 and serving as a critical link in the pharmaceutical supply chain, West Pharmaceutical Services (NYSE: WST) manufactures specialized packaging, containment systems, and delivery devices for injectable drugs and healthcare products.
Why Does WST Fall Short?
- 5.7% annual revenue growth over the last five years was slower than its healthcare peers
- Expenses have increased as a percentage of revenue over the last five years as its adjusted operating margin fell by 5.3 percentage points
- Waning returns on capital imply its previous profit engines are losing steam
West Pharmaceutical Services is trading at $334.67 per share, or 36.4x forward P/E. To fully understand why you should be careful with WST, check out our full research report (it’s free).
One Mid-Cap Stock to Buy:
Super Micro (SMCI)
Market Cap: $24.12 billion
Founded in Silicon Valley in 1993 and known for its modular "building block" approach to server design, Super Micro Computer (NASDAQ: SMCI) designs and manufactures high-performance, energy-efficient server and storage systems for data centers, cloud computing, AI, and edge computing applications.
Why Will SMCI Outperform?
- Market share has increased this cycle as its 61.4% annual revenue growth over the last two years was exceptional
- Massive revenue base of $39.06 billion makes it a well-known name that influences purchasing decisions
- Earnings per share have massively outperformed its peers over the last two years, increasing by 27.8% annually
At $37.28 per share, Super Micro trades at 8.5x forward P/E. Is now the time to initiate a position? See for yourself in our comprehensive research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
